ArticleArthritis research & therapy2013
Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara.
Article in Arthritis research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review.Frontiers in immunology · 2021Pooled it
- PTGDR -441 C/T Polymorphism in a Mexican Mestizo Population with Inflammatory Myopathies: A Pilot Study.Current issues in molecular biology · 2026Article
- The Spectrum of Cutaneous Manifestations in Dermatomyositis: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Preliminary ultrastructural analysis suggests phenotype-specific myofiber alterations in idiopathic inflammatory myopathies.Scientific reports · 2026Article
- IFN-γ +874 T/A Is Associated with High Levels of Sera CPK in Patients with Inflammatory Myopathies.Current issues in molecular biology · 2025Article
- Increased Cytokine Levels in Seronegative Myositis: Potential Th17 Immune Response Implications.International journal of molecular sciences · 2024Article
- Myositis-specific Antibodies: Overview and Clinical Utilization.Rheumatology and immunology research · 2022Review
- Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population.Frontiers in medicine · 2022Article
- High-Dimensional Analysis Reveals Distinct Endotypes in Patients With Idiopathic Inflammatory Myopathies.Frontiers in immunology · 2022Article
- Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.Clinical rheumatology · 2021Article
- Dermatomyositis autoantibodies: how can we maximize utility?Annals of translational medicine · 2021Review
- Concurrent Dermatomyositis, Celiac Disease, and Dermatitis Herpetiformis in a Patient with a History of Morphea.Kansas journal of medicine · 2021Article
- Good response to mycophenolate mofetil on treatment of interstitial lung disease in polymyositis associated with antisynthetase syndrome positive for anti-EJ and anti-Ro52 antibodies.Clinical rheumatology · 2020Article
- Myositis-specific Autoantibodies Reacting to Both Tif1gamma and Mi-2 in a Patient with Juvenile Dermatomyositis.Acta dermato-venereologica · 2020Article
- Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.World journal of pediatrics : WJP · 2020Review
- Classical Dermatomyositis: A Case Report.Clinical, cosmetic and investigational dermatology · 2020Article
- Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.Journal of autoimmunity · 2019Article
- Diffuse Alveolar Hemorrhage in a Patient with Antisynthetase Syndrome.Case reports in rheumatology · 2019Article
- Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.Current rheumatology reports · 2018Review
- Bench to bedside review of myositis autoantibodies.Clinical and molecular allergy : CMA · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAutoantibodies and clinical manifestations in polymyositis/dermatomyositis (PM/DM) are affected by both genetic and environmental factors. The high prevalence of DM and anti-Mi-2 in Central America is thought to be associated with the high UV index of the area. The prevalences of autoantibodies and the clinical manifestations of PM/DM were evaluated comparing two cohorts in Mexico.
methodsNinety-five Mexican patients with PM/DM (66 DM, 29 PM; 67 Mexico City, 28 Guadalajara) were studied. Autoantibodies were characterized by immunoprecipitation using 35S-methionine labeled K562 cell extract. Clinical information was obtained from medical records.
resultsDM represented 69% of PM/DM and anti-Mi-2 was the most common autoantibody (35%), followed by anti-p155/140 (11%); however, anti-Jo-1 was only 4%. The autoantibody profile in adult-onset DM in Mexico City versus Guadalajara showed striking differences: anti-Mi-2 was 59% versus 12% (P = 0.0012) whereas anti-p155/140 was 9% versus 35% (P = 0.02), respectively. A strong association of anti-Mi-2 with DM was confirmed and when clinical features of anti-Mi-2 (+) DM (n = 30) versus anti-Mi-2 (-) DM (n = 36) were compared, the shawl sign (86% versus 64%, P < 0.05) was more common in the anti-Mi-2 (+) group (P = 0.0001). Levels of creatine phosphokinase (CPK) were higher in those who were anti-Mi-2 (+) but they responded well to therapy.
conclusionsAnti-Mi-2 has a high prevalence in Mexican DM and is associated with the shawl sign and high CPK. The prevalence of anti-Mi-2 and anti-p155/140 was significantly different in Mexico City versus Guadalajara, which have a similar UV index. This suggests roles of factors other than UV in anti-Mi-2 antibody production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.